Diagnosing and treating chronic lymphocytic leukemia in 2009

ONCOLOGY

Volumn 23, Issue 12, 2009, Pages

  Kaufman, Matthew ^a   Rubin, Jason ^a   Rai, Kanti ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; CD38 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; GANCICLOVIR; IMMUNOGLOBULIN HEAVY CHAIN; LENALIDOMIDE; LUMILIXIMAB; OFATUMUMAB; PENTOSTATIN; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE SULFATE;

ANEMIA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; FEBRILE NEUTROPENIA; GENE MUTATION; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; TUMOR FLARE;

EID: 72449142771     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Cheson BC, Bennett JM, Grever M, et al: National Cancer Institutesponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996. (Pubitemid 26189840)
2. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer InstituteWorking Group (NCI-WG) 1996 guidelines. Blood 111:5446-5456, 2008.
3. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975.
4. Binet JL, Auquier A, Dighiero G, et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206, 1981. (Pubitemid 11064396)
5. Damle RN, Wasil T, Fais F, et al: Immunoglobulin V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.
6. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.
7. Crespo M, Bosch F, Villamor V, et al: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003. (Pubitemid 36514707)
8. Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:1910-1916, 2004.
9. Del Principe MI, Del Poeta G, Buccisano F, et al: Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108:853-861, 2006. (Pubitemid 44154617)
10. Hamblin T, Orchard J, Ibbotson R, et al: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002. (Pubitemid 34525567)
11. Krober A, Seiler T, Benner A, et al: VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002. (Pubitemid 34864299)
12. Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000.
13. Grever M, Lucas D, DeWald G, et al: Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup phase III trial E2997. J Clin Oncol 25:799-804, 2007. (Pubitemid 350010635)
14. Stilgenbauer S, Dohner K, Dohner H, et al: Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol 76:101-110, 1998. (Pubitemid 28224837)
15. Sturm I, Bosanquet AG, Hermann S, et al: Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477-484, 2003. (Pubitemid 36626360)
16. Lozanski G, Heerema NA, Flinn I, et al: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278-3281, 2004. (Pubitemid 38525651)
17. Gribben J: Molecular profiling in CLL. American Society of Hematology Education Program Book, pp 444-449, 2008.
18. Wierda WG, OBrien S, Wang X, et al: Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109:4679-4685, 2007. (Pubitemid 46827758)
19. Rassenti LZ, Jain S, Keating MJ, et al:Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112:1923-1930, 2008.
20. Rai KR: The role of molecular markers for predicting treatment outcomes in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7(3 suppl 8):6-8, 2009.
21. Dighiero G, Maloum K, Desablens B, et al: Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338:1506-1514, 1998. (Pubitemid 28226278)
22. Shustik C, Mick R, Silver R, et al: Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematol Oncol 6:7-12, 1988. (Pubitemid 18116323)
23. Montserrat E, Fontanillas M, Estape J, for the Spanish PETHEMA Group: Chronic lymphocytic leukemia treatment: an interim report of PETHEMA trials. Leuk Lymphoma 5:89-92, 1991.
24. CLL Trialists Collaborative Group: Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials. J Natl Cancer Inst 91:861-868, 1999.
25. Raphael B, Andersen JW, Silber R, et al: Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 9:770-776, 1991.
26. Jaksic B, Brugiatelli M, Krc I, et al: Comparison of high-dose chlorambucil versus Binets modified CHOP regimen in B-cell chronic lymphocytic leukemia in advanced phase: results of an international multicentric randomized trial. Cancer 79:2107-2114, 1997.
27. French Cooperative Group on Chronic Lymphocytic Leukemia. A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 75:1422-1425, 1990.
28. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000.
29. Eichhorst BF, Busch R, Stauch M, et al: Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG) (abstract 369). Blood 102:109a, 2003.
30. Leporrier M, Chevret S, Cazin B, et al: Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98:2319-2325, 2001.
31. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomized trial of fludarabine vs cyclophosphamide, doxorubicin, and prednisone (CAP) for the treatment of advanced stage chronic lymphocytic leukemia. Lancet 347:1432-1438, 1996. (Pubitemid 26161205)
32. Robak T: Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 40:551-564, 2001. (Pubitemid 32303246)
33. Robak T, Blonski JZ, Kasznicki M, et al: Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 3:244-250, 2002. (Pubitemid 35331384)
34. Weiss MA, Maslak PG, Jurcic JG, et al: Pentostatin and cyclophosphamide: An effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 21:1278-1284, 2003. (Pubitemid 46606404)
35. Kay NE, Geyer SM, Lin T, et al: Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia (abstract 339). Blood 104:100a, 2004.
36. Kay NE, Geyer SM, Call TG, et al: Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405-411, 2007.
37. Knauf WU, Lissichkov T, Aldaoud A, et al, Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009.
38. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-803, 2007.
39. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006. (Pubitemid 43156283)
40. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 trial): A randomized controlled trial. Lancet 370:230-239, 2007. (Pubitemid 47069536)
41. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998. (Pubitemid 28363048)
42. Huhn D, von Schilling C, Wilhelm M, et al: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-1331, 2001.
43. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153-2164, 2001.
44. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21: 1746-1751, 2003.
45. Manshouri T, Do KA, Wang X, et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 1:2507-2513, 2003.
46. OBrien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001. (Pubitemid 32366970)
47. Keating MJ, Flinn I, Jain V, et al: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99:3554-3561, 2002. (Pubitemid 34534522)
48. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in Bcell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005. (Pubitemid 46224116)
49. Stilgenbauer S, Winkler D, Krober A, et al: Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG) (abstract 478). Blood 104, 2004.
50. Hillmen P, Skotnicki AB, Robak T, et al: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616-5623, 2007.
51. Keating M, Coutré S, Rai K, et al: Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 4:220-227, 2004. (Pubitemid 38528876)
52. OBrien SM, Keating MJ, Mocarski ES: Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7:125-130, 2006. (Pubitemid 44596594)
53. Rawstron A, Kennedy B, Evans P: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29-35, 2001.
54. Maloum K, Sutton L, Baudet S: Novel flow cytometric analysis based on BCD5 + subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukemia. Br J Hematol 119:970-975, 2002. (Pubitemid 35463821)
55. Provan D, Bartlett-Pandite L, Zwicky C, et al: Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88:2228-2235, 1996. (Pubitemid 26307926)
56. Wendtner C-M, Ritgen M, Schweighofer CD, et al: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remissionexperience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093-1101, 2004.
57. Lin TS, Donohue KA, Lucas MS, et al: Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101 (abstract 755). Blood 110, 2007.
58. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003.
59. Byrd JC, Rai KR, Peterson BL, et al: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005.
60. Keating MJ, OBrien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005. (Pubitemid 46211313)
61. Tam CS, OBrien S, Wierda W, et al: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975-980, 2008.
62. Hallek M, Fingerle-Rowson G, Fink AM, et al: Immunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) with advanced chronic lymphocytic leukemia (CLL) (abstract 325). Blood 112, 2008.
63. Robak T, Moiseev S, Dmoszynska A, et al: Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia compared with FC alone: final results from the international randomized phase III REACH trial (abstract 1). Blood 112, 2008.
64. Lamanna N, Kalaycio M, Maslak P, et al: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575-1581, 2006. (Pubitemid 46638781)
65. Reynolds C, Di Bella N, Lyons R, et al: Phase III trial of fludarabine, cyclophosphamide, and rituximab vs pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia (abstract 327). Blood 112, 2008.
66. Chanan-Khan MK, Whitworth A, Lawrence D, et al: Clinical activity of lenalidomide in relapsed or refractory chronic lymphocytic leukemia (CLL) patients: updated results of a phase II clinical trial. Leuk Lymphoma 48:S166, 2007.
67. Ferrajoli A, OBrien S, Faderl SH, et al: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297, 2008.
68. Chen C, Harminder P, Xu W, et al: A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL) (abstract 44). Blood 112, 2008.
69. Osterborg A, Kipps TJ, Mayer J, et al: Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludara-bine and alemtuzumab or bulky fludarabine refractory disease: Results from the planned interim analysis of an international pivotal trial. Blood 112:328, 2008.
70. Byrd JC, Castro JE, Flinn IW, et al: Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphoctyic leukemia (CLL): Results from a phase I/II multicenter study (abstract 7003). J Clin Oncol 26:372s, 2008.
71. Lin TS, Heerema NA, Lozanski G, et al: Flavopiridol (Alvocidib) induces durable responses in relapse chronic lymphoctic leukemia (CLL) patients with high-risk cytogenetic abnormalities (abstract 46). Blood 112, 2008.
72. Wierda W, OBrien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005. (Pubitemid 46211312)
73. Frankfurt O, Hamilton E, Duffey S, et al: Alemtuzumab and rituximab combination therapy for patients with untreated CLLa phase II trial (abstract 2098). Blood 112, 2008.
74. Faderl S, Thomas DA, OBrien S, et al: Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413-3415, 2003. (Pubitemid 36857922)
75. Fischer K, Stilgenbauer S, Schweighofer CD, et al: Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): A multicentre phase II trial of the German CLL Study Group (GCLLSG) (abstract 330). Blood 112, 2008.
76. Wierda W, Faderl S, OBrien S, et al: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL (abstract 340). Blood 104:101a, 2004.
77. Gribben JG, Zahrieh D, Stephans K, et al: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106:4389-4396, 2005. (Pubitemid 41775953)
78. Brown JR, Kim HT, Li S, et al: Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant 12:1056-1064, 2006.
79. Dreger P, Corradini P, Kimby E, et al: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21:12-17, 2006.